# TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06589830/  
OnCo record `nct06589830` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab in colorectal cancer, run by Suzhou Teligene Ltd., now recruiting.

## Summary

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06589830 by Suzhou Teligene Ltd., with 80 participants planned, started 2025-05-13 and due to reach its primary completion in 2026-10. Interventions recorded: TL938 Capsules, Trastuzumab. Conditions listed: Colorectal Cancer Metastatic, Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06589830
- Phase: 2
- Setting: A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer
- Sponsor: Suzhou Teligene Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06589830: https://clinicaltrials.gov/study/NCT06589830

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06589830.json